

Applicant : Augustine M. K. Choi et al.
Serial No. : 10/053,535
Filed : January 15, 2002
Page : 2

Attorney's Docket No.: 13681-003002

identifying a patient suffering from a disorder secondary to or resulting in oxidative stress; and

administering to the patient an effective amount of a composition comprising carbon monoxide, wherein the disorder is selected from the group consisting of: emphysema, bronchitis, adult respiratory distress syndrome, cystic fibrosis, pneumonia, interstitial lung disease, primary pulmonary hypertension, secondary pulmonary hypertension, Parkinson's disease and Alzheimer's disease.

43. The method of claim 42, wherein the disorder is emphysema.

44. The method of claim 42, wherein the disorder is bronchitis.

45. The method of claim 42, wherein the disorder is cystic fibrosis.

46. The method of claim 42, wherein the disorder is pneumonia.

47. The method of claim 42, wherein the disorder is interstitial lung disease.

48. The method of claim 42, wherein the disorder is Parkinson's disease.

49. The method of claim 42, wherein the disorder is Alzheimer's disease.

50. The method of claim 42, wherein the disorder is adult respiratory distress syndrome.

51. The method of claim 42, wherein the disorder is primary pulmonary hypertension.

52. The method of claim 42, wherein the disorder is secondary pulmonary hypertension.

53. The method of claim 42, wherein the composition is administered as an inhaled gas.

B² cont

Applicant : Augustine M. K. Choi et al.
Serial No. : 10/053,535
Filed : January 15, 2002
Page : 3

Attorney's Docket No.: 13681-003002

54. The method of claim 53, wherein the gas is administered as a mixture comprising carbon monoxide, nitrogen and oxygen.

55. The method of claim 54, wherein the concentration of carbon monoxide in the mixture is monitored with a carbon monoxide analyzer.

56. The method of claim 42, wherein the patient is a human.

Sub
57. A method of treating asthma in a human patient, comprising:
identifying a patient suffering from asthma; and
administering to the patient an effective amount of a composition comprising carbon monoxide.

B2 cont
58. A method of treating asthma in a patient, comprising:
identifying a patient suffering from asthma; and
administering to the patient an effective amount of a composition comprising carbon monoxide, wherein the composition comprises about 0.0001% to about 0.25% carbon monoxide.

59. The method of claim 58, wherein the patient is a human.

Sub
60. A method of treating cancer in a patient, comprising:
identifying a patient suffering from cancer; and
administering to the patient an effective amount of a composition comprising carbon monoxide, wherein the cancer is selected from a group consisting of: cancer of the stomach, colon, rectum, liver, pancreas, lung, kidney, cervix uteri, corpus uteri, ovary, prostate, testis, bladder, skin, brain/central nervous system, head, neck, mouth, esophagus, larynx and pharynx; Hodgkins disease; non-Hodgkins leukemia; sarcoma; choriocarcinoma; and lymphoma.

Applicant : Augustine M. K. Choi et al.
Serial No. : 10/053,535
Filed : January 15, 2002
Page : 4

Attorney's Docket No.: 13681-003002

- B² cont
61. A method of treating cancer in a human patient, comprising:
identifying a patient suffering from cancer; and
administering to the patient an effective amount of a composition comprising carbon monoxide, to thereby treat cancer in the patient.
62. A method of treating inflammation in a patient, comprising:
identifying a patient suffering from inflammation of at least one organ selected from a group consisting of: kidney, brain, heart, liver, spleen, skin and lung; and
administering to the patient an effective amount of a composition comprising carbon monoxide, wherein the inflammation is of a type selected from a group consisting of: acute, allergic, alterative, atrophic, catarrhal, croupous, fibrinopurulent, fibrinous, immune, hyperplastic, proliferative, subacute, serous and serofibrinous inflammation.
63. A method of treating inflammation in a human patient, comprising:
identifying a human patient suffering from inflammation of at least one organ selected from a group consisting of: kidney, brain, heart, liver, spleen, skin and lung; and
administering to the patient an effective amount of a composition comprising carbon monoxide, to thereby treat inflammation in the patient.
64. A method of treating inflammation in a patient, comprising:
identifying a patient suffering from or at risk of inflammation of at least one organ selected from the group consisting of: kidney, spleen and skin; and
administering to the patient an effective amount of a composition comprising carbon monoxide, to thereby treat inflammation in the patient.
65. A method of treating inflammation in a patient, comprising:
identifying a patient suffering from or at risk of sepsis; and
administering to the patient a composition comprising carbon monoxide in an amount effective to reduce or prevent inflammation secondary to sepsis.

Applicant : Augustine M. K. Choi et al.
Serial No. : 10/053,535
Filed : January 15, 2002
Page : 5

Attorney's Docket No.: 13681-003002

66. A method for promoting wound healing in a patient, comprising:
identifying a patient suffering from a wound; and
administering to the patient an amount of carbon monoxide sufficient to promote
wound healing in the patient.

67. A method of treating sepsis in a patient, comprising:
identifying a patient suffering from or at risk of sepsis; and
administering to the patient a composition comprising carbon monoxide in an
amount effective to treat sepsis in the patient.

68. A method of treating arthritis in a patient, comprising:
identifying a patient suffering from or at risk for arthritis; and
administering to the patient a composition comprising carbon monoxide in an
amount effective to treat arthritis in the patient.

69. A method of treating a patient to reduce oxidative stress associated with hyperoxia,
comprising:
identifying a patient suffering from or at risk for oxidative stress associated with
hyperoxia; and
administering to the patient a composition comprising carbon monoxide in an
amount effective to reduce oxidative stress associated with hyperoxia.